Evaluation of the Efficacy of Systemic Treatments for Alopecia (ESTAA)
Active, not recruiting
- Conditions
- Alopecia Areata
- Registration Number
- NCT06471114
- Lead Sponsor
- University Hospital, Brest
- Brief Summary
The aim of our study was to retrospectively assess the efficacy and safety of systemic treatments in patients with alopecia areata, by recruiting cases from the HUGO network (H么pitaux Universitaires du Grand Ouest), a network of 5 hospitals : Brest, Nantes, Rennes, Angers and Tours.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ACTIVE_NOT_RECRUITING
- Sex
- All
- Target Recruitment
- 250
Inclusion Criteria
- Patient with severe alopecia
- Has received at least one systemic treatment for at least 3 months (among methotrexate, intravenous or oral corticosteroid therapy, Ciclosporin, UVA/UVB phototherapy)
- Patient affiliated to a social security scheme
- Age greater than or equal to 18 years
Read More
Exclusion Criteria
- Patients under legal protection (guardianship, curatorship, etc.)
- Refusal to participate
- Other cause of alopecia
- Follow-up less than 3 months
- Age under 18 years
Read More
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Short-term efficacy and security of systemic treatments From January 2010 to December 2020 Response rates including complete response or partial response or no response for each modality of treatment. and Side effects rate
- Secondary Outcome Measures
Name Time Method Long-term efficacy of systemic treatments From January 2010 to December 2020 Among responders (CR and PR), the maintained response rate and relapse rate
Trial Locations
- Locations (1)
Chu Brest
馃嚝馃嚪Brest, France